

<b>DATE:</b>	8 December 2025
<b>TO:</b>	All Zones: All Healthcare Professionals and Providers
<b>FROM:</b>	Clinical Biochemistry, Alberta Precision Laboratories (APL)
<b>RE:</b>	<b>Standardization of Alpha-1 Antitrypsin Testing</b>

---

**PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE**

---

### Key Message

- Effective **December 18, 2025**, serum and fecal alpha-1 antitrypsin (A1AT) testing will be provincially standardized to one manufacturer (Roche Diagnostics).
- There are several changes:
  - 1) **Serum A1AT:** reference interval change will only impact University of Alberta Hospital (UAH) patients and those collected at Kaye Edmonton Clinic (KEC) Outpatient Labs. (see below)
  - 2) **Fecal A1AT:** no changes in reference interval and reporting.

### Background

- The current testing instrument for A1AT at UAH will no longer be used.
- The assay for serum and fecal A1AT will be switched to an immunoturbidimetry method on the Roche Cobas analyzer at UAH. This is the same method currently employed for serum A1AT testing at the Calgary Hub Laboratory [Diagnostic and Scientific Centre (DSC)].
- Note the change in serum A1AT reference interval will only apply to UAH emergency patients and inpatients, and samples collected at KEC Outpatient Labs.
- Samples from Edmonton Base Lab that were previously sent to Calgary for testing will now be tested at UAH.

### How this will impact you

- Only for UAH: The upper limit of the reference interval for serum A1AT will change

	<b>Current reference interval for serum A1AT</b>	<b>New reference interval for serum A1AT</b>
University of Alberta Hospital patients	0.90 – 2.60 g/L	0.90 – 2.00 g/L
All other patients	0.90 – 2.00 g/L (no change)	

### Action Required

- Note the changes in serum A1AT reference interval change for UAH patients.
- Refer to APL [Test Directory](#) if appropriate.



**ALBERTA PRECISION  
LABORATORIES**

Leaders in Laboratory Medicine

**Inquiries and feedback may be directed to**

- Dr. Albert Tsui, Clinical Biochemist, UAH, 587-782-2674 | [albert.tsui@aplabs.ca](mailto:albert.tsui@aplabs.ca)
- Edmonton Base Lab Clinical Chemist Team, 825-394-1816 | [apl.clinicalchemists@aplabs.ca](mailto:apl.clinicalchemists@aplabs.ca)
- Dr. Ridwan Ibrahim, Clinical Biochemist, DSC Chemistry, 403-770-3505 | [ridwan.ibrahim@albertaprecisionlabs.ca](mailto:ridwan.ibrahim@albertaprecisionlabs.ca)

**This bulletin has been reviewed and approved by**

- Dr. Carolyn O'Hara, Chief Laboratory Medical Officer, APL